Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

Rosa Ahn, Vinay Prasad

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)'. Together they form a unique fingerprint.

Medicine & Life Sciences